SAN DIEGO, CA--(Marketwire - June 29, 2009) -
| Highlighted Links |
Accelrys |
Discovery Studio |
"The new version of Discovery Studio is robust and offers a wide range of functionality," said Manel Lopez, Ph.D., senior scientist at Almirall, a leading pharmaceutical company headquartered in Barcelona, Spain. "I really like the customizable Discovery Guides panel. The new transmembrane protein modeling capabilities of the software are impressive, and will contribute greatly to my research."
About Discovery Studio 2.5
Discovery Studio 2.5 streamlines collaboration and increases research productivity with key enhancements in the following core areas:
-- New scientific developments in the area of small molecule modeling,
fragment-based design, transmembrane protein analysis, and antibody
modeling.
-- Enhanced customizability through new Discovery Guides which allows
users to combine any scientific algorithm and/or functionality in DS to
create a personalized taskflow.
-- Improved Pipeline Pilot integration, allowing users to access
scientific components and protocols to customize workflows, thus providing
flexibility and extensibility of the scientific methods. Subsequently,
these methods are easily deployed within a group via a Web Port or
Microsoft® Sharepoint for effective communication and results-oriented
collaboration.
-- Access to the popular GOLD docking program, licensed by CCDC, allowing
GOLD users to benefit from the robust features of Discovery Studio for
model preparation and docking analysis.
The Discovery Studio architecture also provides access to products developed by partners in Accelrys' ISV ecosystem allowing seamless and sophisticated integration of any third party algorithm.
"Discovery Studio 2.5 represents a significant milestone in the evolution of Accelrys' life science modeling and simulation software," said Frank Brown, chief science officer of Accelrys. "The breadth of validated science now on our platform allows for customizing and automating almost any complex modeling task. This makes the process more robust and easier to use simultaneously, thereby extending the reach of this capability to many more scientists."
For more information about Discovery Studio 2.5 or to download a free trial of Discovery Studio, please visit http://accelrys.com/products/discovery-studio/
About Accelrys, Inc.
Headquartered in San Diego, California, Accelrys develops scientific business intelligence software and solutions for the life sciences, energy, chemicals, aerospace, and consumer products industries. Customers include many Fortune 500 companies and other commercial entities, as well as academic and government entities. Accelrys has a vast portfolio of computer-aided design modeling and simulation offerings which assist customers in conducting scientific experiments 'in silico' in order to reduce the duration and cost of discovering and developing new drugs and materials. Its scientific business intelligence platform underlies the company's computer-aided design modeling and simulation offerings. The Accelrys platform can be used with both Accelrys and competitive products, as well as with customers' proprietary predictive science products. Its flexibility, ease-of-use and advanced chemical, text and image analysis and reporting capabilities enable customers to mine, aggregate, analyze and report scientific data from disparate sources, thereby better utilizing scientific data within their organizations. For more information about Accelrys, visit http://accelrys.com/
Forward-Looking Statements
This press release contains forward-looking statements. Such statements,
including statements relating to the Company's products, their features,
and their impact upon our customers' organizations, are subject to risks
and uncertainties including, but not limited to, the risk that our products
will not be successfully developed, achieve market acceptance, have the
anticipated impact upon our customers' organizations, and other risks and
uncertainties described in documents Accelrys has filed with the Securities
and Exchange Commission, including its most recent report on Form 10-K and
any subsequent interim filings. All forward-looking statements in this
document are qualified entirely by the cautionary statements included in
this document and such filings. These risks and uncertainties could cause
actual results to differ materially from results expressed or implied by
forward-looking statements contained in this document. These
forward-looking statements speak only as of the date of this document.
Accelrys disclaims any intent or obligation to publicly update or revise
any
forward-looking statements contained herein to reflect any change in its
expectations with regard thereto or any change in events, conditions or
circumstances on which any such statement is based.
